Aug 24, 2026 08:01AM
Aug 24, 2026 08:00AM
Aug 11, 2026 04:01PM
Aug 10, 2026 08:02AM
Aug 10, 2026 08:00AM
Jul 13, 2026 04:01PM
Jul 13, 2026 04:01PM Erasca Announces Updated Preliminary Phase 1 Data and Registration-Enabling Plans for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors
Feb 17, 2026 10:48AM
Jan 12, 2026 08:03AM
Nov 19, 2025 09:45AM
Aug 12, 2025 04:01PM
Jun 2, 2025 08:06AM
Jun 2, 2025 08:00AM
May 13, 2025 04:05PM Erasca Reports First Quarter 2025 Business Updates and Financial Results
May 13, 2025 08:04AM
May 13, 2025 08:00AM
Mar 25, 2025 04:31PM
Mar 20, 2025 04:01PM
Nov 12, 2024 04:01PM
Oct 24, 2024 08:02AM
Oct 24, 2024 08:00AM Erasca Announces Strong Momentum for Naporafenib and RAS Targeting Franchise
Sep 25, 2024 08:00AM
Aug 12, 2024 04:01PM
Jun 18, 2024 08:00AM
May 16, 2024 08:03PM
May 16, 2024 08:02PM
May 8, 2024 04:01PM
Apr 24, 2024 04:05PM Erasca Announces Three Presentations at the 2024 ASCO Annual Meeting
Mar 27, 2024 04:01PM
Feb 14, 2024 08:01AM
Feb 14, 2024 08:00AM
Dec 11, 2023 08:03AM
Dec 11, 2023 08:00AM
Nov 28, 2023 08:00AM
Aug 10, 2023 04:01PM Erasca Reports Second Quarter 2023 Financial Results and Business Updates
Jun 22, 2023 04:01PM
Jun 22, 2023 04:01PM
May 25, 2023 05:00PM
May 15, 2023 04:01PM
May 1, 2023 08:03AM
May 1, 2023 08:00AM
Apr 10, 2023 08:04AM Erasca (ERAS) announces Shannon R. Morris, M.D., Ph.D. has been promoted to chief medical officer
Apr 10, 2023 08:00AM
Mar 23, 2023 04:01PM
Mar 23, 2023 04:01PM
Dec 13, 2022 08:01AM
Dec 13, 2022 08:00AM
Dec 13, 2022 08:00AM
Nov 30, 2022 08:02AM Erasca, Inc (ERAS) Announces Clinical Trial Collaboration and Supply Agreement with Pierre Fabre to Evaluate ERAS-007 and Encorafenib Combination
Nov 30, 2022 08:00AM

329,984 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All